deferiprone has been researched along with alpha-synuclein in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bähr, M; Barski, E; Carboni, E; Dambeck, V; Lingor, P; Tatenhorst, L; Tönges, L | 1 |
| Connor, JR; Huang, X; Kim, Y; Stahl, MC | 1 |
| Bush, AI; Finkelstein, DI; McAllum, EJ; McColl, G; Shukla, JJ; Stefanova, N | 1 |
3 other study(ies) available for deferiprone and alpha-synuclein
| Article | Year |
|---|---|
Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein Aggregation.
Topics: alpha-Synuclein; Animals; Cell Count; Deferiprone; Drug Evaluation, Preclinical; Female; Gait Disorders, Neurologic; Humans; Iron; Iron Chelating Agents; Learning Disabilities; Male; Mice; Mice, Transgenic; Neurons; Parkinsonian Disorders; Protein Aggregation, Pathological; Pyridones; Recognition, Psychology; Rotarod Performance Test | 2017 |
H63D variant of the homeostatic iron regulator (HFE) gene alters α-synuclein expression, aggregation, and toxicity.
Topics: alpha-Synuclein; Animals; Autophagy; Cells, Cultured; Deferiprone; Fluoresceins; Gene Knockdown Techniques; Hemochromatosis Protein; Humans; Immunohistochemistry; Iron Chelating Agents; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred C57BL; Mutation; Psychomotor Performance; Transcription Factors | 2020 |
Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Brain; Cerebellum; Ceruloplasmin; Copper; Deferiprone; Disease Models, Animal; Ferritins; Iron; Iron Chelating Agents; Mice; Mice, Transgenic; Multiple System Atrophy; Prefrontal Cortex; Putamen; Substantia Nigra | 2021 |